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ABSTRACT 
Chemokines regulate tissue immunity by recruiting specific subsets of immune cells. 
Mice expressing the E7 protein of HPV16 as a transgene from a keratin 14 promoter 
(K14.E7) show increased epidermal and dermal lymphocytic infiltrates, epidermal 
hyperplasia and suppressed local immunity. Here, we show that CXCL9 and CXCL10 
are overexpressed in non-haematopoietic cells in skin of K14.E7 mice when 
compared with non-transgenic animals, and recruit CXCR3+ lymphocytes to the 
hyperplastic skin. Overexpression of CXCL9 and CXCL10 is not observed in E7 
transgenic mice with mutated Rb gene whose protein product cannot interact with E7 
(K14.E7xRb∆L/∆L) and in consequence lack hyperplastic epithelium. CXCR3+ T cells 
are preferentially recruited by CXCL9 and CXCL10 in supernatants of K14.E7 but 
not K14.E7xRb∆L/∆L skin cultures in vitro. CXCR3 signalling promotes infiltration of 
a subset of effector T lymphocytes that enables donor lymphocyte deficient, E7-
expressing skin graft rejection. Taken together, this suggests that recruitment of 
CXCR3+ T cells can be an important factor in the rejection of precancerous skin 
epithelium providing they can overcome local immunosuppressive mechanisms 
driven by skin-resident lymphocytes. 
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INTRODUCTION 
Cervical intraepithelial neoplasia (CIN) is caused by chronic infection of the cervix 
with high-risk human papilloma virus (HPV). HPV infection often evades immune 
surveillance by various mechanisms (Hasan et al., 2013, Natale et al., 2000, Pacini et 
al., 2015, Tindle, 2002). Although administration of therapeutic HPV vaccines, 
including peptide, protein or dendritic cell based vaccines, to patients with cervical 
intraepithelial neoplasia (CIN) have been associated with disease regression in several 
clinical trials (Hallez et al., 2004, Natale et al., 2000, Van Doorslaer et al., 2010), the 
rate of  regression is not significantly greater than what occurs without intervention 
(Morrow et al., 2013). In addition, induction of CD4+ and CD8+ T cell responses 
after administration of HPV16 E6 and E7 peptides had been accompanied with a 
concomitant induction of inhibitory immune responses, negating potential therapeutic 
effects (Welters et al., 2008).  
 E7 is a papillomavirus encoded oncoprotein that disrupts regular cell cycle by 
interacting with and facilitating degradation of the Rb protein (Brown et al., 2012), 
leading to hyperproliferation of E7 expressing epithelial cells. A transgenic mouse 
model expressing HPV16 E7 viral protein under the control of keratin 14 promoter 
(K14.E7) has been generated to mimic chronic HPV epithelial infection (Herber et al., 
1996). K14.E7 mouse skin shows disrupted keratinocyte differentiation with 
increased expression of stress keratins (6, 16 and 17) (Zhussupbekova et al., 2016) 
and high numbers of skin-infiltrating lymphocytes, resembling observations in human 
CIN lesions (Adurthi et al., 2008, Carrero et al., 2009, Kobayashi et al., 2008). 
Although K14.E7 skin graft is tolerated when grafted onto syngeneic 
immunocompetent recipients (Frazer et al., 2001, Matsumoto et al., 2004), removal of 
T cells from E7-expressing hyperplastic skin significantly enhances rejection of E7 
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transgenic  skin grafts from immune competent recipients (Choyce et al., 2013) 
suggesting the presence of immunosuppressive lymphocytes within the K14.E7 skin 
environment.    
Chemokines direct leukocyte migration and differentiation (Luster, 1998, 
Stoolman, 1989) and also direct cytotoxic lymphocyte infiltration to tumor sites 
(Balkwill, 2004, Chow and Luster, 2014, Mantovani et al., 2004, Spranger et al., 
2017). However, tumor infiltrating lymphocytes may contribute to the 
immunosuppressive environment and thus facilitate tumor growth, survival and 
metastasis (Balkwill, 2003). Clinical trials targeting chemokine inhibition have 
reported promising results against HIV infection (Muniz-Medina et al., 2009, Watson 
et al., 2005, Wood and Armour, 2005) and peripheral and cutaneous T cell lymphoma 
(Ishii et al., 2010, Satoh et al., 2006). An increased expression of CCR6 by CD4+ T 
cells (Choyce et al., 2013) and mast cell recruitment by CCL2 and CCL5 (Bergot et 
al., 2014) has been demonstrated in E7 transgenic skin.  
Here, we show that immune cell infiltration to E7 transgenic skin is a 
consequence of epidermal hyperplasia, and that hyperplasia induces CXCL9 and 
CXCL10 production to recruit a subset of CXCR3+ T cells, promoting rejection of 
grafted E7 transgenic skin depleted of immunosuppressive lymphocytes. 
Consequently, hyperplastic skin causes the infiltration of both suppressive and 
functional lymphocytes and the balance of these two subsets determines the fate of 
K14.E7 skin grafts.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
RESULTS 
E7 interaction with Rb protein is necessary to attract T cells to E7 transgenic 
skin  
K14.E7 transgenic mouse skin exhibits an immune cell infiltrate and regulatory 
cytokine production (Chandra et al., 2016, Choyce et al., 2013, Gosmann et al., 
2014a, Gosmann et al., 2014b, Mattarollo et al., 2010b, Tran le et al., 2015). To 
determine whether the lymphocytic infiltrate observed in E7 transgenic skin requires 
interaction of E7 with Rb protein, we utilized a double transgenic mouse model 
expressing HPV16 E7 and a mutant Rb (K14.E7xRb∆L/∆L) that fails to bind E7 and 
therefore lacks epithelial hyperplasia without perturbing other Rb functions (Balsitis 
et al., 2005, Dick et al., 2000).  The double transgenic mouse has equivalent 
expression of E7 mRNA to K14.E7 mice (Figure 1a).  We compared skin 
immunocytes from female K14.E7 and K14.E7xRb∆L/∆L mice (Rb∆L/∆L and C57BL/6 
mice as controls). K14.E7 skin, but not K14.E7xRb∆L/∆L skin, demonstrated increased 
numbers of CD45+ lymphocytes, CD11b+ non-dendritic cell (DC) cells, CD4+ and 
CD8+ T cells (Figure 1b, d and e). Moreover, decreased numbers of epidermal and 
dermal Langerhans cells (LCs), and higher proportions of epidermal and dermal 
CD11b+ DC, were observed in K14.E7 skin when compared with non-transgenic skin 
(Figure 1c). The numbers and types of antigen presenting cells in K14.E7xRb∆L/∆L 
skin were similar to skin from non-transgenic animals. Keratinocytes in K14.E7 skin 
showed increased major histocompatibility complex II (MHC II) expression, a finding 
consistent with keratinocyte activation in many inflammatory skin diseases (Bjerke, 
1982, Gawkrodger et al., 1987, Lampert et al., 1982, Poulter et al., 1982), whereas 
this was not observed in K14.E7xRb∆L/∆L or non-transgenic skin (Figure 1f).  In 
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contrast to the skin findings, the percentages of lymphocyte subsets in the spleen of 
each transgenic line and non-transgenic animals were similar (Figure S1b).  
Taken together, these results suggest that E7 induced hyperplasia is mediating 
the immune cellular infiltrates that typifies hyperplastic E7-transgenic skin. 
 
Gene expression profiling of E7 transgenic skin  
Transcriptome analysis of skin of C57BL/6, K14.E7 and K14.E7xRb∆L/∆L was 
performed to understand the signals produced in the hyperplastic skin environment 
that promote immune cell recruitment. Differentially expressed genes (Benjamini–
Hochberg P-value<0.01 and log2 fold-change>2) in K14.E7, K14.E7xRb∆L/∆L and 
non-transgenic animals (group A, B and C) were identified using the LIMMA-voom 
R package (Figure S2e). Genes identified with group A and C but not group B 
(n=482) could thus be associated with skin hyperplasia. 
Gene ontology analysis (DAVID 6.8, KEGG) identified that the immune cell 
recruitment signals associated with cell adhesion and chemokine signaling were 
highly correlated with skin hyperplasia (n=482) (Figure 2a). Expression of genes 
encoding chemokines and chemokine receptors was up-regulated in K14.E7 skin but 
not in C57BL/6 nor in K14.E7xRb∆L/∆L skin (Figure 2b). As elevated production of 
IFNγ is observed in E7 transgenic skin (Gosmann et al., 2014a), and chemokines 
CXCL9 amd CXCL10 are induced by Type 1 and 2 interferons and attract CXCR3+ T 
cells, we examined the correlation between the CXCR3 pathway signature in K14.E7 
and non-transgenic skin using the Pathway Interaction Database (PID), curated for 
pre-ranked GSEA analysis. The transcription profile of K14.E7 skin was positively 
correlated with the CXCR3 pathway signature, while the transcription signatures of 
K14.E7xRb∆L/∆L and non-transgenic skin both showed a negative correlation (Figure 
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2c). Up-regulation of the CXCR3 gene set in K14.E7 skin was also observed in 
CAMERA and ROAST analysis (Table S1).  
CXCL9 and CXCL10 are expressed on CD45- cells in hyperplastic K14.E7 
epidermis  
Gene expression analysis suggested that CXCL9/10 chemokine production might 
contribute to CXCR3+ immune cell recruitment in hyperplastic skin. Consistent with 
this hypothesis, we observed that CXCR3+ CD4+ but not CXCR3+ CD8+ or CXCR3+ 
CD4-CD8- TCRβ+ T cells were increased in skin but not spleen from K14.E7 animals, 
when compared to K14.E7xRb∆L/∆L animals (Figure 3a-d). CXCR3+ CD4+ T cells 
from skin draining lymph nodes from K14.E7 mice are not activated when compared 
with cells from non-transgenic mice (Figure 3e). qPCR confirmed up-regulation of 
Cxcl9/10 mRNA expression in skin but not spleen from K14.E7 animals when 
compared with K14.E7xRb∆L/∆L or non-transgenic animals (Figure 4a). Flow 
cytometric analysis showed that cells in the epidermis of K14.E7 mice express more 
CXCL9/10 (Figure 4b and c) than epidermal cells from K14.E7xRb∆L/∆L and non-
transgenic mice, and that the majority of CXCL9/10 expression in K14.E7 epidermis 
was by CD45- cells (Figure 4d and e) and was dependent on IFNγ signalling (Figure 
S3a and b). Similarly, whole skin RNAseq showed reduced expression of Cxcl9 
mRNA in E7 transgenic animals lacking the IFNγ receptor (Figure S3c). DCs (gated 
on CD11c+MHCII+CD45+) of K14.E7 epidermis, express low to negative level of 
CXCL9 and CXCL10 when compared to the DCs from non-transgenic skin (Figure 
S4). Immunofluorescent staining showed that in K14.E7 skin, the expression of 
CXCL10 was particularly prevalent at the basal layer of the epidermis and amongst 
fully differentiated keratinocytes, whereas CXCL9 was expressed uniformly in the 
suprabasal region of the epidermis (Figure 4f). Although some MHCII+ cells from the 
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dermis of K14.E7 express CXCL9 and CXCL10 (Figure 4g), most expression 
appeared to be in MHCII- cells in the epidermis.  
CXCR3 promotes T lymphocyte recruitment to E7-associated hyperplastic skin 
To assess whether T cell migration to hyperplastic skin was dependent on CXCR3, an 
in vitro chemotaxis trans-well assay was performed, using T cells induced to express 
CXCR3 (Nakajima et al., 2002). Supernatant from skin explants from K14.E7 mice 
attracted significantly more CXCR3+ CD4 and CD8 T cells (Figure 5a and b) than 
supernatant from K14.E7xRb∆L/∆L or non-transgenic skin. Moreover, CXCR3+ T cell 
migration was significantly reduced by a CXCL9/10 neutralising antibody (nAb) 
(Figure 5a-c), confirming a role for CXCL9 and CXCL10 in T cell migration in this 
assay. No significant CXCR3+ T cell migration was observed with supernatant from 
mice unable to express IFN-γ (K14.E7xIFNγ-/-; IFNγ-/-), supporting the hypothesis 
that CXCL9 and CXCL10 production is IFN-γ dependent. Expression of CXCR3 on 
migrated CXCR3+ T cells was lower on cells that migrated in response to K14.E7 skin 
supernatant (Figure 5c), suggesting internalization of ligand-engaged receptors.   
 
CXCR3 signalling is required for T cell subset infiltration into K14.E7 skin 
grafts 
To further assess the role of CXCR3 chemokine signals in the recruitment of 
lymphocytes to K14.E7 skin in vivo,  CXCR3+ T cells, derived from CD45.1+ 
congenic B6.SJL.Ptprca mice, were transferred to non-transgenic CD45.2+ animals 
bearing well healed CD45.2+ K14.E7 grafts. Graft recipients were subsequently 
administered a CXCR3 antagonist-AMG487 or vehicle control (Figure 5d). Skin 
grafts harvested after four days of AMG-487 treatment had less TCRβ+ CD45.1+ cells 
(~30 cells per cm2 of skin graft) when compared to vehicle controls (~60 cells per cm2 
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of skin graft). Numbers of endogenous CD45.2 cells in the grafts were not altered by 
AMG-487 treatment (Figure 5e). Moreover, no significant difference in CD45.1+ T 
cell infiltration was found in lymph node or spleen of grafted animals (Figure 5f). The 
data shows that engagement of CXCR3 is required for a subset of T cells to localize 
in K14.E7 transgenic skin.  
 
Antagonizing CXCR3 signal does not enable K14.E7 skin graft rejection 
Skin grafting was performed to investigate the function of skin infiltrating CXCR3+ T 
cells in the context of K14.E7 skin hyperplasia. K14.E7xRag-/- skin grafts were shown 
to be spontaneously rejected (Choyce et al., 2013) and produce chemokines CXCL9 
and CXCL10 (Figure 6a). Interestingly, while the dominant CD45- cell population in 
the epidermis of K14.E7xRag-/- mice produces minimal CXCL9/10, a small 
CXCL9/10-producing subpopulation that is not seen in K14.E7xIFNγ-/- mice is 
observed. This, therefore, may not be IFNγ induced. B6.SJL.Ptprca mice receive 
K14.E7 and K14.E7xRag-/-  skin 7 days after recipients were immunized with E7 
peptide. Grafted mice were treated with the CXCR3 antagonist-AMG487 or vehicle 
control (Figure 6b). Host-derived CXCR3+ T cells were recruited to skin grafts in 
small numbers in vehicle control mice, but were largely absent in mice treated with 
the antagonist (Figure 6c). More CD4+CXCR3+ than CD8+CXCR3+ cells were 
recruited to K14.E7 skin graft (Figure 6d), consistent with the higher frequency of 
CD4+CXCR3+ cells found in the skin of K14.E7 (Figure 3a). K14.E7xRag-/-  skin 
grafts were rejected (defined as 50% of skin graft shrinkage) when the recipient mice 
were administered with vehicle control, but were not rejected when treated with 
CXCR3 antagonist. K14.E7 skin grafts onto C57BL/6 recipients were tolerated in 
both groups as previously shown (Figure 6e-f). This suggests that infiltrating 
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CXCR3+ T cells are an effector population that is required for graft rejection in donor 
lymphocyte deficient skin grafts.  Therefore, in the absence of donor lymphocyte 
mediated suppression, CXCR3+ effector T cell populations are able to effect skin graft 
rejection.  
DISCUSSION 
In this manuscript, we utilized K14.E7xRb∆L/∆L mice, which resembles normal skin in 
immune landscape and gene expression profile, to separate the hyperplastic phenotype 
from the local HPV16 E7 expression. We demonstrated that epithelial hyperplasia 
induced by HPV16E7 protein expression is required for the infiltration of 
immunocytes and the induction of CXCL9 and CXCL10 chemokines, which can 
attract CXCR3+ T cells to the skin. These findings pose two questions: firstly, how 
does the epithelial hyperplasia impact on infiltrated lymphocytes; secondly, how do 
these chemokines contribute to the local immune responses that is a feature of E7 
transgenic skin. 
We demonstrated that the presence of E7-induced epithelial skin hyperplasia 
can also alter the expression profile of skin chemokines. Importantly, disruption of the 
E7-Rb interaction and epithelial hyperplasia in our study resulted in a reduction in 
CXCL9 and CXCL10 production within the skin. A change in skin chemokines is 
also seen in several other skin disorders and epithelial proliferation associated with 
wound healing (Gillitzer and Goebeler, 2001). For instance, CXCL9 and CXCL10, 
induced by wounding, facilitates epithelial repair through production of growth 
factors (Yates et al., 2009) and assists in preventing infection by promoting pathogen 
specific immune responses (Thapa and Carr, 2008). CXCL9/ and CXCL10 can be 
induced in damaged skin from myeloid cells and activated keratinocytes. This attracts 
CXCR3+ immunocytes as a feature of many inflammatory skin disorders (Flier et al., 
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2001). Similarly, epithelial hyperproliferation, induced by deletion of the Mi-2β 
chromatin remodeler, results in CXCL9 and CXCL10 chemokine production in skin, 
and subsequently recruit both effector and regulatory CD4+ T cell populations 
(Kashiwagi et al., 2017). Moreover, CXCR3+ CD4 and CD8 T cells were found to be 
important in enhancing epidermal proliferation in a chemical skin tumorigenesis 
model (Winkler et al., 2011). The effect of hyperplasia on  chemokine recruitment of 
immune cells can also be observed in murine hyperplastic cervix (mucosal) induced 
by either transgenic expression of HPV16 E7 or by treatment with estradiol, another 
commonly associated carcinogen for cervical oncogenesis. Genes associated with 
immune trafficking (Cxcl13, Ccl3, Cxcr2) and inflammatory responses (IL-1α, TNFα, 
Irf1) were the top up-regulated categories in both models of hyperplastic cervix 
(Cortes-Malagon et al., 2013). Whether there is an additive effect of the different 
causes of hyperplasia on immune cell trafficking and immune response was not 
explored but this effect is likely to be an important aspect for cervical disease 
progression. In support of this, neoplastic progression could be delayed when non-
antigen specific inflammation was reduced by depleting CD4+ T cells (Daniel et al., 
2003) in a different HPVE7-induced epithelial hyperplasia mouse model (Arbeit et 
al., 1994). Up-regulation of CXCR2 and its ligands CXCL1, 2, 3 and 5 in K14.E7 
skin (Figure 2b) may contribute to increased keratinocyte proliferation as CXCR2 
deficient animals showed a delayed wound healing process in terms of 
epithelialization and neovascularization (Devalaraja et al., 2000). Together, these 
findings support the idea that epithelial proliferation is the likely driver of elevated 
chemokine production and the latter is further required for progression of the disease. 
Although expression of CXCL9 and CXCL10 was dramatically increased in 
K14.E7 skin, antagonizing CXCR3 did not change the outcome for K14E7 skin grafts 
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on immunocompetent recipients. However, when local immunosuppression was 
removed by utilizing lymphocyte-deficient K14E7 grafts, these grafts were promptly 
rejected (defined as 50% of graft shrinkage) in a CXCR3 dependent manner.  
However, graft rejection was then prevented by blocking CXCR3 interactions, 
suggesting that CXCR3+ T cells function as effector cells responsible for graft 
rejection in these circumstances. But how does this infiltrating CXCR3+ effector 
population fail to reject K14E7 skin grafts on immunocompetent recipients? We 
hypothesise that insufficient CXCR3+ effector cells are recruited to overcome local 
suppressive mechanisms and/or that the infiltrating population undergoes 
programming toward a phenotype ineffective for graft rejection.  While CXCR3+ T 
cells are clearly effector cells in our model, they represent only a small subset of the T 
cells within the skin, suggesting that other chemokines may be involved in epithelial 
hyperplasia-induced T cell recruitment. Recently, chemokine CXCL14 has been 
shown to be down-regulated in a HPV16E7-dependent manner and impacts on anti-
tumor immune response. Restoration of Cxcl14 expression in HPV-positive mouse 
oropharyngeal carcinoma cells enables the recruitment of NK, CD4+ and CD8+ T cells 
to tumor draining lymph node (Cicchini et al., 2016). Our previous studies have 
shown that CCR6+ CD4 T cells can be recruited via CCL20 to the hyperplastic 
K14E7 skin (Choyce et al., 2013). CCR6 regulates the migration of regulatory T cells 
(Yamazaki et al., 2008) but depletion of Foxp3+ regulatory T cells from either K14.E7 
skin graft donor or graft recipients failed to reject K14.E7 skin (Mattarollo et al., 
2011). In this study, the majority of CXCR3 expression was observed on TCRβ+CD4-
CD8- T cells (CXCR3+CD4+ and CXCR3+CD8+ T cells comprised, 2.2% and 0.6%,  
of total T cells respectively, while the total population of CXCR3+ T cell is 7.5%). 
This unusual CD4-CD8- subset of αβT cells can represent NKT cells, conventional T 
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cells that have downregulated CD8 expression to form proinflammatory effector cells 
or alternatively, a population of regulatory cells (Brandt et al., 2017, Godfrey et al., 
2004, Zhang et al., 2001). The presence of a regulatory T cell population in K14.E7 
skin, most likely NKT cells, prevents rejection of E7 transgenic skin by 
immunocompetent graft recipients although the chemokine attracting NKT cells to 
K14E7 skin remains unknown (Mattarollo et al., 2010a). Although no differential 
expression of CXCR3 was observed in non-transgenic, K14.E7 and K14.E7xRb∆L/∆L, 
this double negative T cell population could also potentially contribute to skin 
immunity in a MHC-independent manner (Tikhonova et al., 2012, Van Laethem et al., 
2007).  
Ideally, immunotherapeutic intervention targeting effector immune cell 
recruitment should induce more efficient immune responses to combat cancers. As 
chronic IFNγ stimulation has profound impact on i) CXCL9 and CXCL10 chemokine 
expression/signalling and ii) the fate of K14.E7 skin grafts, one possible strategy may 
be to increase the infiltration of CXCR3+ T cells to HPV-infected lesions and 
overcome the local suppressive environment.  
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MATERIALS AND METHODS 
Animals 
Mice were maintained in Translational Research Institute Biological Research Facility 
under specific pathogen free conditions. Female mice were used at 8-12wk of age. 
C57BL/6, K14.E7 (Herber et al., 1996), Rag-/- and B6.SJL.Ptprca mice were obtained 
from Animal Resources Centre (Perth, Australia). IFNγ-/-  and IFNγR-/- mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME). Heterozygous Rb∆L/∆L 
transgenic mice (Isaac et al., 2006) were obtained from Dr. Fred Dick. Homozygous 
Rb∆L/∆L mice were generated by backcrossing C57BL/6 for 10 generations. 
K14.E7xIFNγ-/-, K14.E7xIFNγR-/-, K14.E7xRag-/- and K14.E7xRb∆L/∆L mice were 
generated by mating heterozygous K14.E7 with homozygous IFNγ-/-, Rag-/-  and 
Rb∆L/∆L, respectively. All procedures were approved by the University of Queensland 
Animal Ethics Committee (UQDI/367/13/NHMRC and UQDI/452/16).   
 
FACS and Antibodies  
FACS analysis were undertaken as previously described (Mattarollo et al., 2010a). 
Foxp3 Fix/Perm Concentrate and Diluent kit was used for intracellular staining 
(eBioscience, San Diego, USA). CXCL9 and CXCL10 were stained intracellularly 
with unconjugated goat anti-mouse polyclonal Ab (R&D, MN, USA) followed by PE-
conjugated secondary donkey anti-goat IgG H&L Ab (Abcam, Cambridge, UK). 
Anti-mouse monoclonal Abs to CD45.2 (104), CD45.1 (30-F11), CD8α (53-6.7), 
TCRβ (H57-597), CD11b (M1/70), EpCAM (G8.8), CD19 (6D5), MHCII (I-A/I-E) 
(M5/114.15.2), IFNγ (XMG1.2), CXCR3 (CXCR3-173), CXCR3 (Met1-Leu367), 
CD3 (145-2C11), CD4 (GK1.5), CD11c (HL3) and corresponding isotype controls 
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were purchased from Biolegend (San Diego, USA), eBioscience (San Diego, USA), 
BD Bioscience (San Jose, USA) and R&D (MN, USA).  
 
RNA extraction, reverse transcription and qPCR 
RNA Extraction was performed as described (Zhussupbekova et al., 2016). For each 
reverse transcription, 1 μg of extracted RNA was processed using a SuperScriptIII kit 
(Life technology, MA, USA). Primers sequences can be found in Table S2. qPCR was 
carried out on Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR System.  
 
Sequencing and analysis, GSEA and gene ontology analysis 
RNA sequencing and raw data processing were done as previously described 
(Zhussupbekova et al., 2016). Detailed methods for GSEA and gene ontology analysis 
can be found in the supplementary materials and methods.  
 
Skin Grafting and Reagents 
Grafting was done as previously described (Choyce et al., 2013). Animals were given 
CXCR3 antagonist-AMG487 (Tocris, No. 3387, Bristol, UK) 3 µg/g body weight in 
DMSO, or DMSO alone, subcutaneously. E7 peptide (RAHYNIVTF) was 
synthesized by Auspep Pty Ltd, (Melbourne, Australia), with purity >80%. 
 
Transwell migration assay  
Splenocytes were activated (supplementary methods), and 5 x 105 activated cells in 
100 µl were seeded into a 5 µm pore trans-well insert (Corning, No. 3421, NY, USA). 
Supernatants from in vitro skin cultures (supplementary methods) were diluted with 
RPMI in 1:2 ratio, with a final volume of 750 µl. As controls, recombinant CXCL9 
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(250-18, Peprotech, NJ, USA), CXCL10 (250-16, Peprotech, NJ, USA), neutralizing 
antibodies for CXCL9 (AF-492-SP, R&D, MN, USA), CXCL10 (AF-466-SP, R&D, 
MN, USA) or goat IgG isotype control (AB-108-C, R&D, MN, USA) were added to 
the bottom well of the transwell culture. Cells were incubated at 37°C for 60 minutes 
and the cells in the bottom wells were collected for FACS analysis.  
 
Statistical analysis 
Prism 7 (GraphPad Software, La Jolla, CA) software was used for statistical analysis 
and to prepare the plots. Unless otherwise stated, all analyses were done using one-
way ANOVA, with Bonferroni’s multiple comparison test. Unpaired Student’s t-test 
and two-way ANOVA were used in Figure 6e and Figure 6f and j, respectively.  All 
plots show mean value with SEM. Result significance was shown, where *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001.  
 
Other methods can be found in Supplementary Method section.  
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FIGURE LEGENDS 
Figure 1. Effect of E7 expression on local immune responses is minimal in the 
absence of E7 induced epithelial proliferation 
Skin from K14.E7 transgenic was compared with K14.E7xRb∆L/∆L and C57BL/6 
mice. (a) Expression of E7 mRNA relative to an internal control, Hprt. n>3 (b-f) 
FACS analysis of skin infiltrating immune cell populations. (b) live CD45+ cells,; (c) 
epidermal and dermal antigen presenting cell populations- EpCAM+CD11b+ (LC) and 
EpCAM- CD11b+ (CD11b+ DC) as a percentage of CD11c+MHCII+ CD45+ cells; (d) 
CD11b+ non-DCs (as a percentage of CD3Ɛ-CD11c- CD45+ cells); (f) MHCII+CD45- 
cells. Error bars showing mean+/-SEM.  
 
Figure 2. Overexpression of mRNA for chemokine receptors and ligands in E7 
transgenic skin 
(a) Pathway analysis of 482 genes differentially displayed in association with 
hyperplastic skin. Bars, top 10 pathways ranked by -log10 of B-H P-value; dots, 
number of genes in a particular gene ontology group. (b) Heat map of chemokine 
genes expression in C57BL/6, K14.E7 and K14.E7xRb∆L/∆L skin. (c) GSEA of 
CXCR3 pathway signature to the mRNA profile of K14.E7 vs. K14.E7xRb∆L/∆L and 
K14.E7 vs. C57BL/6. Black and grey dots, subset in the leading edge of the gene set, 
where 25/40 and 23/40 genes were identified, respectively.  
 
Figure 3. CXCR3 enriched in K14.E7 but not K14.E7xRb∆L/∆L skin  
CXCR3 expression on CD4+ and CD8+ T cells in skin and spleen. (a and b) 
Representative flow cytometry plots pre-gated on live CD45+TCRβ+ cells. a, skin; b, 
spleen.  (c and d) Quantitative results from skin and spleen of 3-5 mice. (e) 
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Representative plots showing expression of activation markers by CXCR3+ and 
CXCR3- CD4 T cells from lymph nodes.  
 
Figure 4. CXCL9/10 expression in skin is mostly by epidermal CD45- cells  
(a) Expression of Cxcl9/10, normalized with Hprt, relative to C57BL/6, in skin and 
spleen. (b) Intracellular CXCL9/10 were assessed for live cells from epidermis and 
dermis of K14.E7 and compared with K14.E7xRb∆L/∆L and C57BL/6 mice. (d) 
Expression of CXCL9/10 on CD45-, DCs (CD11c+MHCII+) and T cells (TCRβ+) in 
K14.E7 epidermis. (c and e) Quantitative data showing mean percentage and ΔMFI 
of (b) and (d), respectively. ΔMFI calculated by subtracting signal MFI from isotype 
control MFI. (a-e) Error bars showing mean+/-SEM with n>3 of each sample. (f and 
g) Immunofluorescent staining of CXCL9/10 (red) within K14.E7 skin. Blue, DAPI; 
green, MHCII. Scale bar= 200 µm in (f) 100 µm in (g).  
 
Figure 5. CXCR3+ T cells migrate to hyperplastic skin environment in vitro and 
in vivo  
(a-c) T cell migration assay. 0mM, medium control; +CXCL9/10, 50nM CXCL9; 
10nM CXCL10; nAb, neutralizing antibody to CXCL9/10 at 200 ng/ml. Isotype Ab 
was included in K14.E7 supernatant. (c) MFI of surface CXCR3 on migrated T cells 
with. All compared to +CXCL9/10. (d-f) K14.E7 skin grafts were placed onto 
C57BL/6 (CD45.2) recipient. On day 21, 5*106 activated B6.SJL.Ptprca (CD45.1) 
splenocytes were transferred intravenously. CXCR3 antagonist-AMG487 or vehicle 
control was injected subcutaneously for four days. On day 25, skin grafts were 
excised and lymph node and spleen were harvested for FACS analysis. (e) Number of 
CD45.1/ CD45.2 cells found in grafts on day 25. (f) Percentage of TCRβ+CD45.1 
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cells found in different tissues. (d-f) Pooled result from two-independent experiments. 
All error bars showing mean+/-SEM with n>3. 
 
Figure 6. CXCR3+ T cells influence on graft rejection  
(a) CXCL9/10 expression level in epidermis and dermis from K14.E7xRag-/- mouse 
expressed as percentage compared to K14.E7. Representative plot showed from n>3. 
(b-f) Skin graft recipients received E7-peptide (50µg) subcutaneously 7 days before 
grafting. Recipients were grafted with K14.E7 (left) and K14.E7xRag-/- (right) ear 
skin and treated with either vehicle control or AMG487 daily. N>5 per treatment 
group. All error bars showing mean+/-SEM. (c) CXCR3+ T lymphocytes 
(TCRβ+CD45.1) in K14.E7 skin grafts treated with vehicle control or AMG487. Cell 
numbers were normalized by skin graft size (per cm2). Unpaired student t-test with 
*p<0.05 performed. (d) Percentage of CXCR3+CD4+ and CXCR3+CD8+ cells in 
K14.E7 skin graft treated with vehicle control. (e) Skin grafts on day 27, scale bar= 
10 mm. (f) Percentage of graft survival.  
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